SLN360
silence therapeutics
['silence thera']
yesterday at #aha22, curtis rambaran, silence vp clinical sciences, presented at a poster session about a new analysis of our drug candidate to potentially treat high levels of lipoprotein(a) or #lpa. if you missed it, see the analysis: #silenceisgolden 
We are developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference. Nasdaq:SLN Guidelines: https://t.co/BplIZBk56w